International Journal of Diabetes in Developing Countries最新文献

{"title":"Impacts of a 12-week aerobic, resistance, and combined exercise training on serum FAM19A5, glucose homeostasis, and novel cardiovascular risk factors among adults with obesity","authors":"Ehsan Mir, Alireza Shamseddini, Najmeh Rahimi, Behzad Bazgir","doi":"10.1007/s13410-024-01315-7","DOIUrl":"https://doi.org/10.1007/s13410-024-01315-7","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>To determine the impacts of 12 weeks of aerobic, resistance, or combined training on FAM19A5, glucose homeostasis, body composition, and physical performance in obese men.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Fifty-eight obese men [age = 49 ± 6 years; body mass index (BMI) = 29 ± 2 kg m⁻²] were randomly assigned to aerobic training (<i>n</i> = 14), resistance training (<i>n</i> = 15), combined training (<i>n</i> = 15), and control (<i>n</i> = 14) groups. Interventions were three sessions per week for 12 weeks.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>FAM19A5 levels remained unaltered in all three intervention groups. However, insulin concentrations, triglyceride, HOMA-IR, VAI, TyG, and fat% declined in all three interventions, whereas VO_2max increased. In addition, glucose levels, LAP, body weight, and BMI were reduced in aerobic and combined groups, while systolic blood pressure was reduced in resistance and combined programs. We also observed a significant reduction in low-density lipoprotein following only combined exercises and a significant increase in high-density lipoprotein after only aerobic exercises. There was a significant negative relationship between serum levels of FAM19A5 and HOMA-IR.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>This is the first report to assess the influence of exercise interventions on circulating FAM19A5 levels in obese adults. Although FAM19A5 levels remained unchanged in all three interventions, our work provides information to support that aerobic, resistance, and combined regimens can be effective in improving HOMA-IR, triglyceride, systolic blood pressure, BMI, and aerobic performance in obese men. Additional studies with large sample size should be conducted to further clarify the underlying mechanisms.</p>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":"17 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139752410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of insulin glargine U-300 as compared to insulin glargine U-100 in oral antidiabetic (OAD) failure cases—record-based observational study","authors":"Shambo S. Samajdar, Shashank R. Joshi, Sougata Sarkar, Santanu K. Tripathi, Satyabrata Sahoo, Nandini Chatterjee, Jyotirmoy Pal, Rutul A. Gokalani","doi":"10.1007/s13410-024-01317-5","DOIUrl":"https://doi.org/10.1007/s13410-024-01317-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background </h3><p>Type 2 diabetes is a significant public health concern that affects over 537 million adults worldwide. Oral antidiabetic (OAD) failure can be a complex management issue in patients with type 2 diabetes. Insulin glargine U-300 is a newer type of basal insulin with more consistent pharmacological effects than traditional insulin glargine.</p><h3 data-test=\"abstract-sub-heading\">Objective</h3><p>This study aimed to assess the safety and effectiveness of insulin glargine U-300 as compared to insulin glargine U-100 in Indian type 2 diabetes patients who had experienced OAD failure.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>This is a record-based observational study conducted on type 2 diabetes patients who had experienced OAD failure.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The study involved 389 cases (189 on insulin glargine U-300 and 200 on insulin glargine U-100). It was found that 56.6% and 58.1% of patients had reduced fasting glucose levels below 130 mg/dl after 1 month of treatment, and 78.8% and 76.1% had a reduction after 3 months following the use of insulin glargine U-300 and insulin glargine U-100, respectively. In patients on glargine U-300 and insulin glargine U-100, the mean fasting plasma glucose decreased from 241.05 ± 65.93 mg/dl at baseline to 142.61 ± 55.19 mg/dl (<i>p</i> &lt; 0.05) and similarly from 250.68 ± 61.41 to 140.27 ± 48.29 mg/dl (<i>p</i> &lt; 0.05) at the end of the first month, respectively. The incidence of hypoglycemia was comparatively fewer in patients using insulin glargine U-300 as compared to those using insulin glargine U-100 (8.1% vs. 6.7%, <i>p</i> &lt; 0.05).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The results suggest that insulin glargine U-300 is an effective and safer treatment option than insulin glargine U-100 for Indian patients with OAD failure. These findings have the potential to improve the management of type 2 diabetes patients with OAD failure globally.</p>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":"9 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139752199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The HNF1B mutations and deletion associated with diabetes and their resulting diabetic phenotypes: a systematic review","authors":"","doi":"10.1007/s13410-024-01319-3","DOIUrl":"https://doi.org/10.1007/s13410-024-01319-3","url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Objective</h3> <p>Mutations or deletion in <em>HNF1B</em> gene has been found to be related to a special type of monogenetic diabetes (<em>HNF1B</em>-DM). However, the phenotypic features of <em>HNF1B</em>-DM and the related gene abnormalities remain unclear.</p> </span> <span> <h3>Methods</h3> <p>We systemically reviewed the literature associated with <em>HNF1B</em>-DM in PubMed, China National Knowledge Infrastructure (CNKI), and Wanfang databases. The mutations and clinical data of <em>HNF1B</em>-DM were recorded. The phenotypes between mutations and deletion in <em>HNF1B</em> were analyzed.</p> </span> <span> <h3>Results</h3> <p>In total, 261 eligible individuals were included. 64 mutations were reported in 134 patients, and another 127 patients carried a large deletion in <em>HNF1B</em> gene. The mutations were distributed throughout from exons 1 to 7, including missense, nonsense, frameshift, and splice site mutation. Body weight index (BMI) was available for 69 patients; 55 patients (79.7%) were normal or underweight. Of the 131 patients with available family history, 105 (80.2%) reported a family history of diabetes. Data on age at diagnosis of diabetes was recorded in 210 patients with a mean of 23.7 years. Estimated glomerular filtration rate was recorded in 52 patients with a median of 47.00 ml/min per 1.73 m². Renal cysts were in 78.9%, pancreatic dysplasia in 78.6%, and hypomagnesemia in 64.3% of the patients. The patients with <em>HNF1B</em> deletion had different diabetic phenotypes from the patients with <em>HNF1B</em> point mutation.</p> </span> <span> <h3>Conclusions</h3> <p><em>HNF1B</em>-DM patients were with younger onset age, normal or low BMI, renal cyst, pancreatic dysplasia, and hypomagnesemia. The patients should be recommended for genetic testing to differentiate <em>HNF1BDM</em> from other young-onset diabetes earlier.</p> </span>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":"54 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139752083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"24-h Glucose profile of patients with gestational diabetes mellitus and comparison with pregnant women with normoglycemia","authors":"","doi":"10.1007/s13410-024-01311-x","DOIUrl":"https://doi.org/10.1007/s13410-024-01311-x","url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Objective</h3> <p>To study the 24-h glucose profile of patients with mild GDM using the commercially available Abbot Libre continuous glucose monitoring system (CGMS) and compare them with pregnant women with normoglycemia (gestational age comparable).</p> </span> <span> <h3>Methods</h3> <p>A case control study conducted between 2019-2020 followed eligible pregnant women diagnosed with GDM according to Diabetes in Pregnancy Study Group India criteria, after the placement of a CGMS.</p> </span> <span> <h3>Results</h3> <p>Twenty-one GDM patients whose mean age was 27.1 ± 3.3 years with gestational age 28 weeks (24–32) and thirty pregnant women with normoglycemia whose mean age was 25.7 ± 4.2 years and gestational age 26 weeks (23–34) were enrolled in the study. Fasting, pre-breakfast, 2 h post lunch, day time and lowest nocturnal glucose were significantly higher in the GDM group than in controls. Glycemic variability indices like standard deviation of blood glucose, J index, and mean amplitude of glycemic excursions were also significantly higher in GDM patients. GDM patients spent more time above &gt;140 mg/dl than controls.</p> </span> <span> <h3>Conclusion</h3> <p>GDM patients, who have mild hyperglycemia but not overt diabetes, also have an abnormal 24 h glucose profile as compared to normal pregnancy.</p> </span>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":"19 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139585409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of Lp-PLA2 for coronary artery disease in type 2 diabetes mellitus patients: an observational study","authors":"","doi":"10.1007/s13410-024-01312-w","DOIUrl":"https://doi.org/10.1007/s13410-024-01312-w","url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Objective</h3> <p>Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by elevated blood glucose levels, which can result in a variety of complications, including coronary artery disease (CAD). Lp-PLA2 is a proinflammatory enzyme associated with low-density lipoprotein (LDL) particles in the circulation and is thought to be a biomarker for CAD risk.</p> </span> <span> <h3>Methods</h3> <p>The purpose of this investigation was to evaluate the diagnostic utility of serum lipoprotein-associated phospholipase A2 (Lp-PLA2) levels in type 2 diabetes mellitus (T2DM) patients with and without coronary artery disease (CAD). Utilizing receiver operating characteristic (ROC) curves, the diagnostic efficacy of Lp-PLA2 was evaluated.</p> </span> <span> <h3>Results</h3> <p>Lp-PLA2 levels were substantially higher in T2DM patients without cardiovascular disease (146.7 ng/mL 88.4) compared to HC (103.3 ng/mL 21.7) and T2DM + CAD (124.31 ng/mL 11.7). There was no statistically significant correlation between Lp-PLA2 levels and age, Hba1c, LDL, or Lp(a) in T2DM patients without CAD. Lp-PLA2 levels were not significantly associated with age (p = 0.97), HbA1c (<em>p</em> = 0.41), LDL (<em>p</em> = 0.59), or Lp(a) (<em>p</em> = 0.56), as determined by multiple linear regression analysis. The area under the curve (AUC) for Lp-PLA2 in T2DM without CAD was calculated to be 0.76, with a 95% confidence interval (CI). The sensitivity and specificity of a termination point of &gt; 115 ng/mL were 0.70 and 0.68, respectively. For patients with T2DM + CAD, the AUC was 0.73 with a 95% confidence interval, and a threshold point of &gt; 115 ng/mL yielded sensitivity and specificity values of 0.73 and 0.75, respectively.</p> </span> <span> <h3>Conclusions</h3> <p>In T2DM patients with or without CAD, serum Lp-PLA2 concentrations may serve as a diagnostic marker. The cutoff value of &gt; 115 ng/mL exhibited excellent sensitivity and specificity, especially in T2DM patients without CAD. This finding suggests the clinical utility of Lp-PLA2 as a diagnostic tool for identifying those at risk for CAD in the context of T2DM.</p> </span>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":"13 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139561178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers of endothelial dysfunction (vWF), hypofibrinolysis (PAI-1) and metabolic syndrome components in hypertensive patients with and without thrombotic complications","authors":"David Santiago-Germán, Rosa María Jiménez-Alvarado, Alfredo Leaños-Miranda, Irma Isordia-Salas","doi":"10.1007/s13410-023-01299-w","DOIUrl":"https://doi.org/10.1007/s13410-023-01299-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Essential hypertension is associated with increased risk for atherothrombotic disease.</p><h3 data-test=\"abstract-sub-heading\">Objective</h3><p>The aims were to determine and compared the plasma concentration of von Willebrand Factor (vWF) and Plasminogen Activator Inhibitor type 1 (PAI-1) in hypertensive patients with and without atherothrombotic disease and the influence of antihypertensive treatment on those biomarkers.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Total of 341 individuals were included, 83 normotensive subjects and 258 hypertensive patients (43 with and 215 without atherothrombotic disease). The vWF and PAI-1 were measured by ELISA technique. Multivariate linear and quantile regression analysis were performed.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>There was higher vWF concentration (<i>p</i> &lt; 0.001) and PAI-1 (<i>p</i> &lt; 0.001) in hypertensive compared with normotensive individuals. The vWF level was correlated with hypertension, older age and glucose, explaining 26%, 70% and 86% of vWF variability. Increased PAI-1 levels were correlated with glucose, triglycerides, HbA1c, explaining 66%, 73% and 90% of variability. In contrast, lower PAI-1 concentration was determined by older age.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>We found higher levels of vWF and PAI-1 in hypertensive patients, with highest concentration of vWF in patients with hypertension and thrombotic disease and the highest of PAI-1 in hypertensive patients without atherothrombotic disease. The lowest level of vWF was determined in patients with angiotensin II receptor blocker, and for the PAI-1 level in patients with calcium channel blocker medication. The lowest concentration of both biomarkers was present in patients who were treated with 3 or more drugs. Hypertension, older age, disorders in glucose and lipid metabolism were the main determinants of vWF and PAI-1 variability.</p><h3 data-test=\"abstract-sub-heading\">Graphical Abstract</h3>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":"24 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139517351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetic retinopathy screening guidelines for Physicians in India: position statement by the Research Society for the Study of Diabetes in India (RSSDI) and the Vitreoretinal Society of India (VRSI)-2023","authors":"Manisha Agarwal, Padmaja Kumari Rani, Rajiv Raman, Raja Narayanan, Sreenivasamurthy L., Anil Virmani, Ramachandan Rajalakshmi, Sudha Chandrashekhar, Brij Mohan Makkar, Sanjay Agarwal, Mahesh Shanmugam Palanivelu, Muralidhar Naveenam Srinivasa, Kim Ramasamy","doi":"10.1007/s13410-023-01296-z","DOIUrl":"https://doi.org/10.1007/s13410-023-01296-z","url":null,"abstract":"<p>Diabetic retinopathy (DR) is a leading cause of blindness among working-age adults worldwide. India is the diabetes capital of the world and one in five adults is said to have diabetes in India. With the increase in diabetes, there is an increasing burden of diabetic retinopathy (DR). All patients with diabetes have a risk of losing vision due to DR. The prevalence of diabetic retinopathy is 12.5%; out of which, 4% are said to have vision-threatening diabetic retinopathy (VTDR) The early stages of DR are symptomless, necessitating a proactive screening for an early detection of DR in all people with diabetes before they develop VTDR. This is a position statement jointly developed by RSSDI (Research Society for the Study of Diabetes in India) and VRSI (Vitreo Retinal Society of India) to provide guidelines for Physicians on DR screening in India. These guidelines emphasize the need for regular DR screening of all people with diabetes. It is recommended that the Physicians establish an effective DR screening model in their clinics, eg., a non-mydriatic fundus camera utilizing artificial intelligence (AI) algorithms for fundus photography to identify referral or non-referral DR. This will facilitate early detection and timely referral to an ophthalmologist thereby preventing VTDR. The need to create public awareness regarding blindness due to DR and a collaboration between Physicians and ophthalmologists for the management of diabetes, opportunistic screening of DR, and timely management of DR may play a crucial role in decreasing the burden of blindness secondary to diabetes.</p>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":"184 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139507733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors affecting the prolongation of glycemic time in range among children with type 1 diabetes using continuous glucose monitoring systems: A case control study","authors":"Kowalczyk-Korcz Emilia, Szypowska Agnieszka","doi":"10.1007/s13410-024-01310-y","DOIUrl":"https://doi.org/10.1007/s13410-024-01310-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Time in range is a reliable measure of the risk of diabetes complications. High percentage of patients with diabetes fail to achieve the recommended time in range (TIR) target of 70–180 mg/dl (3.9–10 mmol/l) &gt;70%.</p><h3 data-test=\"abstract-sub-heading\">Objective</h3><p>This study aimed to identify factors influencing TIR prolongation.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Children aged 1–17 years with &gt;1-year type 1 diabetes (T1D) duration, treated with continuous subcutaneous insulin infusion (CSII) ≥3 months, using continuous glucose monitoring (CGM) or intermittently scanned CGM (is-CGM) ≥1 month, and with a registration time &gt;70% were included. Data were collected during routine diabetology visits at an outpatient clinic. Insulin pump and CGM or is-CGM reports in the most recent 14 days were recorded using a dedicated software. Legal caregivers were also asked to complete a questionnaire on how the patients use the insulin pump functions and eating habits.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A sample of 110 patients was categorized into two groups: those with TIR &gt;70% and TIR ≤70%. TIR &gt;70% group presented with repeated hyperglycemia and a high glycemic variability coefficient of variation. We noted an acceptable hypoglycemia rate (3%), regardless of the TIR value. Patients with TIR &gt;70% predominantly used predictive low glucose suspend system, maintained adequate intervals between insulin delivery and meal consumption, used the “bolus calculator” function, and more frequently created electronic reports.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Hyperglycemia and high glycemic variability prevent patients from achieving the target TIR. Advanced features in the CGM systems, premeal insulin bolus, and patients’ involvement in diabetes treatment are the main factors contributing to TIR prolongation.</p>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":"26 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139500567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iranian patients with diabetes and COVID-19-associated mucormycosis: Characteristics, manifestations, and mortality risk factors","authors":"Mohammadreza Salehi, Alireza Esteghamati, Sadegh Khodavaisy, Nasim Khajavi Rad, Alireza Abdollahi, Sayyed Amirsina Alemzadeh, Sadaf Nasserisina, Azin Tabari, Farzad Pakdel, Saeed Mohammadi, Neda Joorabloo, Mahsa Abdorahimi, Mehrdad Shavandi, Soghra Rabizadeh","doi":"10.1007/s13410-024-01309-5","DOIUrl":"https://doi.org/10.1007/s13410-024-01309-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>This study evaluated the mortality risk factors in Iranian patients with diabetes mellitus (DM) and COVID-19-associated mucormycosis (CAM).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>This retrospective study was conducted on confirmed CAM cases with DM. Only patients with a confirmed history of COVID-19 within the last 3 months were included. The patients were divided into the survived and deceased groups, and each group’s characteristics were studied and compared. Patients were also studied according to their DM status (known or unknown case).</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 106 patients were included. The mortality rate was 25.5%. The most common underlying disease (hypertension, 41.5%) was significantly higher in the deceased group. Sixty-five patients (62.5%) were known cases of DM. The mean duration of DM was 12.46 years. There was a significant relationship between the DM history and mortality rate (84.6% vs. 15.4%, <i>p</i> = 0.007). The history of ICU admission was 8 times higher in unknown DM patients (<i>p</i> = 0.011, OR = 8.000, CI = 1.60–39.95). The mean HbA1C was significantly different in known DM cases (9.36 ± 2.03 vs. 8.02 ± 2.40, <i>p</i> = 0.004). The mean first day FBS, mean first BS in emergency room, and mean FBS on the first hospitalization week were 171, 202, and 167.2 mg/dL, respectively. Although mortality was significantly related to hyperglycemic state of fasting and non-fasting BS levels (<i>p </i>&lt; 0.05), it was not related to HbA1C.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Patients with diabetes and COVID-19 had uncontrolled fasting and non-fasting glucose levels during mucormycosis episode. Hypertension, history of DM, and the lack of glucose control during recent hospitalization can be associated with a poor outcome.</p>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":"70 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139500571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between impaired sensitivity to thyroid hormones and MAFLD with elevated liver enzymes in the euthyroid population","authors":"","doi":"10.1007/s13410-023-01308-y","DOIUrl":"https://doi.org/10.1007/s13410-023-01308-y","url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Objective</h3> <p>There is a delicate interplay between thyroid hormones and thyrotropin (TSH) and metabolic homeostasis. However, the role of thyroid hormone sensitivity in metabolic health, particularly in relation to metabolic dysfunction-associated fatty liver disease (MAFLD) and associated complications such as elevated liver enzymes and free fatty acid (FFAs) has not been elucidated in euthyroid populations.</p> </span> <span> <h3>Methods</h3> <p>A total of 3929 euthyroid adults from the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University were included in this study. Thyroid hormone sensitivity indices were calculated by thyroid feedback quantile-based index (TFQI), TSH index (TSHI) and thyrotropin thyroxine resistance index (TT4RI). Associations between thyroid hormones sensitivities and risk of MAFLD, MAFLD with elevated liver enzymes, MAFLD with elevated FFAs were assessed with logistic regression.</p> </span> <span> <h3>Results</h3> <p>After adjustment for multiple risk factors, adjusted odds ratio (AOR) of the fourth versus the first TFQI_FT4 quartile for MAFLD, MAFLD with elevated liver enzymes, and MAFLD with elevated FFAs were 1.778 (95% CI 1.378, 2.293), 1.466 (1.105, 1.945), and 1.936 (1.479, 2.534), respectively (all <em>p</em>&lt;0.001). Per 1 SD in TFQI_FT4, ORs increased 2.27 (95% CI 1.74, 2.97) for MAFLD, 2.05 (1.51, 2.78) for MAFLD with elevated liver enzymes, and 2.43 (1.82, 3.24) for MAFLD with elevated FFAs. The other sensitivity to thyroid hormones indices showed similar associations for MAFLD and MAFLD with elevated liver enzymes.</p> </span> <span> <h3>Conclusions</h3> <p>These findings have important implications for understanding the role of thyroid hormone sensitivity in metabolic health, particularly in relation to MAFLD and associated complications such as elevated liver enzymes and FFAs. TFQI_FT4, TFQI_FT3, TSHI and TT4RI can be used as new indicators for predicting MAFLD and MAFLD with elevated liver enzymes.</p> </span>","PeriodicalId":50328,"journal":{"name":"International Journal of Diabetes in Developing Countries","volume":"27 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139408451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}